Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.

Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.

News Market Reaction – LUNG

+1.94%

9 alerts

+1.94% Session move

+2.2% Peak Tracked

-18.9% Trough Tracked

$132.45M Market Cap

1.2x Rel. Volume

In the trading session that priced this news, LUNG gained 1.94%, reflecting a mild positive market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -18.9% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial Valve, Chartis^® Pulmonary Assessment System, LungTraX^TM Platform, and StratX^® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx^®, AeriSeal^®, Chartis^®, StratX^®, and Zephyr^® are registered trademarks and LungTraX^TM is a trademark of Pulmonx Corporation.

Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com

FAQ

When is Pulmonx (LUNG) presenting at the Canaccord Genuity Growth Conference?

Pulmonx will present on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.

How can investors access Pulmonx's (LUNG) presentation at the Canaccord conference?

Investors can access both the live and archived webcast of the presentation through the Investors section of Pulmonx's website at investors.pulmonx.com.

What does Pulmonx (LUNG) specialize in?

Pulmonx is a global leader in minimally invasive treatments for lung disease.

Where is the Canaccord Genuity Growth Conference being held?

The conference is being held in Boston.